Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Leukaemias
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Leukaemias
    Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
    TopAbstracts in Leukemias 11/26/2008 - (DGNews)
    TopAbstracts in Leukemias 11/19/2008 - (DGNews)
    TopAbstracts in Leukemias 11/12/2008 - (DGNews)
    TopAbstracts in Leukemias 11/05/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Leukaemias

    Webcasts/CME archive

     Recent cases - Leukaemias
      A Patient with Glycogen Storage Disease Type Ib Presenting with Acute Myeloid Leukemia (AML) Bearing Monosomy 7 and Translocation t(3;8)(q26;q24) after 14 Years of Treatment with Granulocyte Colony-Stimulating Factor (G-CSF): A Case Report
      Successful Outcome of Langerhans Cell Histiocytosis Complicated by Therapy-Related Myelodysplasia and Acute Myeloid Leukemia: A Case Report
      Hairy Cell Leukaemia Presenting with Ascites, Pleural Effusion and Increased CA 125 Serum Level
      Down Syndrome with Microgranular Variant of Acute Promyelocytic Leukemia in a Child: A Case Report
      Brucella Bacteremia in Patients with Acute Leukemia: A Case Series

      Cases archive
        




      my personal edition > leukaemias > news
      divider

        E-Mail this DGNews to a colleague

      DGNews


      Cephalon Oncology Compound Lestaurtinib (CEP-701) Granted Orphan Drug Designation for Acute Myeloid Leukemia

      FRAZER, P.A. -- April 4, 2006 -- Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for lestaurtinib (CEP-701) for the treatment of acute myeloid leukemia (AML). The orphan drug designation will provide a seven-year period of marketing exclusivity for this indication from the date of final FDA marketing approval of the compound.

      FDA may designate a medication as an orphan drug if the product is intended to treat a rare disease or condition affecting less than 200,000 Americans annually. An estimated 12,000 people in the United States were diagnosed with AML in 2005, according to the American Cancer Society. Approximately 25-30% of these patients have a FLT-3 genetic mutation that is associated with a poorer prognosis for relapse and survival.

      Lestaurtinib
      Discovered by Cephalon scientists, lestaurtinib is a potent inhibitor of several tyrosine kinases including FLT-3 and TrkA. This orally active, investigational compound is in a Phase 2/3 clinical trial. It is a targeted agent against AML in patients at first relapse from standard induction chemotherapy and whose disease presents with a genetic alteration known as a FLT-3 activating mutation.


      SOURCE: Cephalon Inc.



      E-Mail this DGNews to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send